NENC Medicines Subcommittee and NTAG decisions – April 2024

The decisions made at the NENC Medicines Subcommittee April 2024 meeting can now be found at: https://ntag.nhs.uk/meetings/decision-summaries/

This includes the recommendations made by NTAG at its March 2024 meeting and NICE Technology appraisals from the 1st December 2023 to 31st January 2024.

The following guidelines/position statements were approved and can be found at:

The following guidelines/position statements were archived/deleted from the NTAG website:

  • NENC Patient Specific Factors to Consider When Choosing a DOAC in NVAF

Medicines Committee decision – NICE TA953, TA956 – March/April 2024

The decision made with regard to these NICE 30 day TAs can now be found at: https://ntag.nhs.uk/meetings/decision-summaries/

  • NICE TA 953: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema
  • NICE TA956: Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over

NENC Medicines Subcommittee and NTAG decisions – February 2024

The decisions made at the NENC Medicines Subcommittee February 2024 meeting can now be found at: https://ntag.nhs.uk/meetings/decision-summaries/

This includes the recommendations made by NTAG at its January 2024 meeting and NICE Technology appraisals from the 1st October 2023 to 30th November 2023.

The following guidelines/position statements were approved and can be found at:


NENC Medicines Subcommittee and NTAG decisions – December 2023

The decisions made at the NENC Medicines Subcommittee December 2023 meeting can now be found at: https://ntag.nhs.uk/meetings/decision-summaries/

This includes the recommendations made by NTAG at its November 2023 meeting and NICE Technology appraisals from the 1st August 2023 to 30th September 2023.

The following guidelines/position statements were approved and can be found at:


NTAG Website – refresh – Nov 2023

NTAG website has undergone a bit of refresh to hopefully make things a little easier to find.

All guidelines and shared care guidelines can now be found on newly created separate share care and guidelines pages accessed from the top menu bar. Nothing has disappeared from the site but may have moved from being under recommendations to the new share care guidelines and separate guidelines pages.


Medicines Committee decision – NICE TA929 – Nov 2023 and publication of NENC Amiodarone shared care guideline

The decision made with regard to this NICE 30 day TA can now be found at: https://ntag.nhs.uk/meetings/decision-summaries/

  • TA929 – Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction

The following guideline approved at October 2023 Medicines Subcommittee has now been published and can be found at:


Medicines Committee decision – NICE TA918, TA920, TA925, TA927 – Nov 2023

The decision made with regard to these NICE 30 day TAs can now be found at: https://ntag.nhs.uk/meetings/decision-summaries/

  • TA918 – Bimekizumab for treating axial spondyloarthritis
  • TA920 – Tofacitinib for treating active ankylosing spondylitis
  • TA925 – Mirikizumab for treating moderately to severely active ulcerative colitis
  • TA927 Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments

NENC Medicines Subcommittee and NTAG decisions – October 2023

The decisions made at the NENC Medicines Subcommittee October 2023 meeting can now be found at: https://ntag.nhs.uk/meetings/decision-summaries/

This includes the recommendations made by NTAG at its September 2023 meeting and NICE Technology appraisals from the 1st June 2023 to 31st July 2023.

The following guidelines/position statements were approved and can be found at:

The following guidelines will be published shortly once final version with version control on is received from the authors:

  • NENC Amiodarone shared care guideline

NENC Medicines Subcommittee and NTAG decisions NICE TA916 – October 2023

The decision made with regard to NICE 30 day TA916 for Bimekizumab for treating active psoriatic arthritis can now be found at: https://ntag.nhs.uk/meetings/decision-summaries/


NENC Medicines Subcommittee and NTAG decisions – September 2023

The decisions made at the NENC Medicines Subcommittee September 2023 meeting can now be found at: https://ntag.nhs.uk/meetings/decision-summaries/

This includes the recommendations made by NTAG in July 2023 meeting and NICE Technology appraisals from the 1st April 2023 to 31st May 2023.

The following guidelines/position statements were approved and can be found at: